Analyst Price Target is GBX 90
▲ +27.17% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for NIOX Group in the last 3 months. The average price target is GBX 90, with a high forecast of GBX 90 and a low forecast of GBX 90. The average price target represents a 27.17% upside from the last price of GBX 70.77.
Current Consensus is
Buy
The current consensus among 2 contributing investment analysts is to buy stock in NIOX Group.
NIOX Group plc is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings.
Headquartered in the UK and listed on the London Stock Exchange (ticker: NIOX), the company operates internationally, serving healthcare professionals in over 50 countries. NIOX is committed to enabling more precise and personalised care for patients with respiratory conditions, with a focus on quality, innovation, and scientific excellence.
Read More